Navigation Links
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting

Ozarelix improved LUTS symptoms and urine flow over 28-week period

QUEBEC CITY, May 23, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Spectrum Pharmaceuticals presented an abstract outlining detailed Phase 2 results for AEterna Zentaris' fourth-generation luteinizing hormone-releasing hormone (LHRH/GnRH) antagonist, ozarelix, in benign prostatic hyperplasia (BPH). Results indicate that ozarelix was well tolerated and demonstrated statistically significant as well as clinically meaningful efficacy in the treatment of lower urinary tract symptoms (LUTS) secondary to BPH. Results also showed no statistically significant impact on quality of life or erectile function. The abstract was presented yesterday afternoon at the American Urological Association (AUA) Annual Meeting being held this week at the Anaheim Convention Center in Anaheim, California.

"We are encouraged by these data with ozarelix and look forward to seeing further results from the fully-enrolled Phase 2b trial, said David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris. "With cetrorelix in an ongoing Phase 3 program and ozarelix completing a Phase 2b trial this year, we are fortunate to be leading the LHRH antagonist class with two very promising compounds for the treatment of BPH."

Details

The abstract #93629 (Poster #1552) titled, "The efficacy and safety of ozarelix, a novel GnRH antagonist in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)" reviewed results of a randomized, double-blind, placebo-controlled, multi-center, dose-ranging Phase 2 trial in BPH.

Ozarelix was given intramuscularly (IM) to men with moderate to severe LUTS due to BPH, to assess the compound's efficacy and safety. Eligible patients were treated with placebo for 4 weeks to establish b
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/24/2009)...RNewswire/--MAQUETCardiovascularLLC,aleadingprovid...thassignedaguaranteedtwo-yearcontractwithNovation,...s,tobethesolesourceproviderofsurgicaldevicesforbea...greement,whichrunsthroughOctober31,2012,MAQUETCard...devicesanddisposablesuppliestothemembersofVHAInc.a...
(Date:11/24/2009)...ewswire-FirstCall/--Orexigen®Therapeutics,Inc...nthetreatmentofobesity,todayannouncedthatonNovembe...dofDirectorsgrantedaninducementstockoptiontopurcha...itsnewlyappointedHeadoftheGlobalContraveProgram. ,...ptiontotheextentpermittedbylawandhasanexercisepric...
(Date:11/24/2009)...4/PRNewswire-FirstCall/--BioSpecificsTechnologiesC...opingfirstinclasscollagenase-basedproducts,todayan...esentattheupcomingPiperJaffray21stAnnualHealthCare...NewYorkPalaceHotelinNewYork,NY. ,, Alivewebcast...ts"intheInvestorRelationssectionoftheCompany,swebs...
Breaking Medicine Technology:MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices 2MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices 3Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 2Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 3Empire BlueCross BlueShield Launches Art Heals Program with Museum for African Art Greater New York Hospital Association 59161 1Empire BlueCross BlueShield Launches Art Heals Program with Museum for African Art Greater New York Hospital Association 59161 2Empire BlueCross BlueShield Launches Art Heals Program with Museum for African Art Greater New York Hospital Association 59161 3Producers of New PBS Series Joined By Experts to Reveal Science Behind Happiness 59158 1Producers of New PBS Series Joined By Experts to Reveal Science Behind Happiness 59158 2Producers of New PBS Series Joined By Experts to Reveal Science Behind Happiness 59158 3Producers of New PBS Series Joined By Experts to Reveal Science Behind Happiness 59158 4Producers of New PBS Series Joined By Experts to Reveal Science Behind Happiness 59158 5Greenway Medical Technologies Continues to Lead the Evolution of Healthcare Automation at National Health IT Week in Washington D C 5345 1Greenway Medical Technologies Continues to Lead the Evolution of Healthcare Automation at National Health IT Week in Washington D C 5345 2Greenway Medical Technologies Continues to Lead the Evolution of Healthcare Automation at National Health IT Week in Washington D C 5345 3Greenway Medical Technologies Continues to Lead the Evolution of Healthcare Automation at National Health IT Week in Washington D C 5345 4
...April 27 Pomegranate juice may slow the progres... according to new long-term research results being...of the American Urological Association (AUA). Rese...t for localized prostate cancer could benefit from...clinical trial followed a total of 48 participants...
...(R) System Capabilities Enable Powerful New TB Dia...heid (Nasdaq: CPHD ) today announced the release...r the European Directive on In Vitro Diagnostic ...icians will have access to a rapid test that can s... (MTB) and resistance to rifampicin (RIF), a comm...
Other Medicine Technology:Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6
(Date:11/24/2009)...ench and Spanish . , Researchers at the U...alled ,gene E, which leads to the death of tumour... and prevents their growth. The importance of this...ce the potent drugs that are currently used, so th... , This research was conducted by Ana Rosa Rama...
(Date:11/24/2009)...rman . , Internationally viewed, medical car... as far as survival is concerned. However, other a...rm consequences of the disease are still insuffici...ion of the Institute for Quality and Efficiency in... on 16 October 2009. , Establish mandatory qual...
(Date:11/24/2009)...lastic surgery experts from the American Society o...s the recently proposed cosmetic surgery tax. , ...s) November 24, 2009 -- Leading plastic surgery ex...s (ASPS), are available to discuss the recently pr...e nation’s leading plastic surgery experts a...
(Date:11/24/2009)...th undesirable blood levels, analysis shows , ...mal cholesterol levels can significantly increase ..., U.S. researchers analyzed data on 6,860 parti...titute,s Framingham Heart Study. None of the parti...e at the start of the study. After about 26 years ...
(Date:11/24/2009)...evice regulatory consulting firm Emergo Group rece..., distributors and industry service providers abou...ion plans and their outlook for 2010. , ...2009 -- Global medical device regulatory consulti...al device and IVD manufacturers, distributors and ...
Breaking Medicine News(10 mins):Health News:Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage 2Health News:In Germany, children with cancer have a high probability of survival 2Health News:In Germany, children with cancer have a high probability of survival 3Health News:Leading Plastic Surgery Experts Available to Discuss Proposed ,Cosmetic Surgery Tax 2Health News:Cholesterol Plays Role in Heart Failure Risk 2Health News:Medical Device Industry Positive About 2010 – Survey 2
...n proposed by researchers at Medical College of Wi... assess the improvement in survival rate in cardia... The study would be funded by the National Heart...ardiac arrest and severe traumatic injury, and wou...
...ropean breast cancer conference (EBCC-5) had docto...st cancer research and improve patient care//. Bre...n women. But as of now the survival rates are impr...ation for Research and Treatment of Cancer (EORTC)...
...to the study conducted by Theodore Blaine, M.D., a...bia University Medical Center and an attending// s...aluronate, a drug that is FDA-approved for osteoar...other Cox-2 inhibitors. After that people went for...
...ts suffering from chronic shoulder pain were left ...dvil or to go for a surgery//, after the safety co...s were raised. But a research done by Columbia Uni... the shoulder pain. The study was presented ...
...g maker Sanofi-Aventis SA announced on Thursday th...d its cancer drug Taxotere to treat patients with ...e can be used in combination with chemotherapy dru...es of breast cancer and lung cancer. Certain types...
...rs believe that enforced bicycle helmet laws impro...this view aside.// Several studies suggest t... head injuries than non-wearers. But Dorothy Robin...e public health. She reviewed data from coun...
Other Medicine News:Health News:An Effective Drug Identified for Shoulder Pain 2Health News:New Drug For Treating Chronic Shoulder Pain 2Health News:New Drug For Treating Chronic Shoulder Pain 3Health News:Can Enforcing Bicycle Helmet Laws Avoid Head Injuries? 2
...matched precision and reproducibility, so you can ... viral load values they can trust.,you detect si...ical decision points - without the variability see...hoose VERSANT HIV bDNA, consider this: it's the on...
...unodeficiency Virus (HIV-1) undergoes mutations in...ti-viral drug treatment. Some of the mutations hav...action of these drugs, diminishing the effectivene...n HIV-1 that correlate with drug resistance provid...
...assays provide superior specificity, thereby reduc...on. Vironostika HIV-1 Microelisa System is an enz...f antibody to HIV-1 in serum, plasma or dried bloo...System is an enzyme-linked immuosorbent assay for ...
OraQuick ADVANCE Rapid HIV-1/2 Antibody Test
Medicine Products: